Form 4: Vaxcyte CFO Exercises Stock Options and Sells Shares

Andrew Guggenhime, CFO of Vaxcyte, Inc., executed stock options and sold shares on October 25, 2024.

Summary

• On October 25, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc. (PCVX), exercised stock options to acquire 19,108 shares of common stock at a price of $20.93 per share.
• Simultaneously, Guggenhime disposed of 19,108 shares of common stock at a price of $20.93.
• Following these transactions, Guggenhime directly owns 109,491 shares of Vaxcyte common stock and holds options for 125,892 shares.
• The stock options vest monthly, contingent upon continuous service with Vaxcyte.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative implications for the company's overall prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
• The vesting schedule of 1/48 monthly is a common vesting arrangement for employee stock options.
• Lock-up agreements are frequently used in connection with IPOs or other significant corporate events to restrict insiders from selling shares for a specified period.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, depending on their interpretation of insider trading activity.
• The vesting schedule impacts employees holding stock options.

Key Dates